Peringkat dalam Saham
#13779
Evommune, Inc. is a United States-based clinical-stage biotechnology company... Evommune, Inc. is a United States-based clinical-stage biotechnology company dedicated to advancing novel therapeutic solutions. Their primary focus lies in addressing the underlying mechanisms of chronic inflammatory diseases. Initial clinical development efforts are concentrated on conditions such as chronic spontaneous urticaria, atopic dermatitis, and ulcerative colitis. The company's investigational portfolio features EVO756, which is being developed for the treatment of chronic spontaneous urticaria (CSU) and atopic dermatitis (AD), and EVO301, intended for atopic dermatitis (AD) and ulcerative colitis (UC). Established in 2020, Evommune operates from its headquarters in Palo Alto, California.
Kapitalisasi Pasar
$458.19M
Perubahan (1 hari)
-3.26%
Perdagangan Evommune, Inc. (EVMN)
Harga EVMN dengan kapitalisasi pasar B
Kapitalisasi pasar dari Evommune, Inc.(EVMN)
Kapitalisasi Pasar: $458.19M
Per August 2026, Evommune, Inc. memiliki kapitalisasi pasar sebesar $458.19M. Ini menjadikan Evommune, Inc. sebagai perusahaan 13779th paling bernilai di dunia menurut data kami. Kapitalisasi pasar adalah nilai total saham beredar dari perusahaan publik dan biasanya digunakan untuk mengukur seberapa besar nilai sebuah perusahaan.
Riwayat kapitalisasi pasar Evommune, Inc. dari 2025 hingga 2026
EVMN dibandingkan dengan 5 teratas stocks paling populer
| Harga EVMN |
|
Aset B |
Pasar B |
Hasil |
|
|
|
|
$5.327T
|
+1,162,480.60%
|
|
|
|
|
$4.632T
|
+1,010,918.15%
|
|
|
|
|
$4.062T
|
+886,437.60%
|
|
|
|
|
$3.796T
|
+828,408.76%
|
|
|
|
|
$2.781T
|
+606,898.68%
|
